Jpmorgan Chase & CO Collegium Pharmaceutical, Inc Transaction History

Jpmorgan Chase & CO

$1.51 Trillion
Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 211,757 shares of COLL stock, worth $9.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

211,757

Previous 211,757 -0.0%

Holding current value

$9.74 Million

Previous $7.41 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	BUY	$29.75 - $39.59 $4.23 Million - $5.63 Million	142,281 Added 204.79%	211,757 $7.41 Million
Q1 2025 May 12, 2025	SELL	$28.04 - $33.91 $370,548 - $448,120	-13,215 Reduced 15.98%	69,476 $2.07 Million
Q4 2024 Feb 12, 2025	SELL	$28.61 - $41.86 $5.57 Million - $8.14 Million	-194,513 Reduced 70.17%	82,691 $2.37 Million
Q3 2024 Dec 26, 2024	BUY	$31.4 - $39.07 $5.52 Million - $6.87 Million	175,892 Added 173.61%	277,204 $10.7 Million
Q3 2024 Nov 08, 2024	BUY	$31.4 - $39.07 $5.52 Million - $6.87 Million	175,892 Added 173.61%	277,204 $10.7 Million

Q2 2024 Dec 26, 2024	SELL	$31.36 - $39.99 $5.52 Million - $7.03 Million	-175,892 Reduced 63.45%	101,312 $3.26 Million
Q2 2024 Aug 12, 2024	SELL	$31.36 - $39.99 $754,019 - $961,519	-24,044 Reduced 19.18%	101,312 $3.26 Million
Q1 2024 Dec 26, 2024	SELL	$31.23 - $40.91 $4.74 Million - $6.21 Million	-151,848 Reduced 54.78%	125,356 $4.87 Million
Q1 2024 May 10, 2024	SELL	$31.23 - $40.91 $3.14 Million - $4.11 Million	-100,392 Reduced 44.47%	125,356 $4.87 Million
Q4 2023 Dec 26, 2024	SELL	$21.16 - $30.8 $1.09 Million - $1.58 Million	-51,456 Reduced 18.56%	225,748 $6.95 Million
Q4 2023 Feb 12, 2024	BUY	$21.16 - $30.8 $1.73 Million - $2.52 Million	81,851 Added 56.88%	225,748 $6.95 Million
Q3 2023 Nov 14, 2023	BUY	$21.23 - $24.28 $741,118 - $847,590	34,909 Added 32.03%	143,897 $3.22 Million
Q2 2023 Aug 11, 2023	SELL	$21.06 - $24.0 $384,281 - $437,928	-18,247 Reduced 14.34%	108,988 $2.34 Million
Q1 2023 May 18, 2023	BUY	$23.0 - $29.88 $592,342 - $769,529	25,754 Added 25.38%	127,235 $3.05 Million
Q1 2023 May 11, 2023	SELL	$23.0 - $29.88 $498,939 - $648,186	-21,693 Reduced 17.61%	101,481 $2.43 Million
Q4 2022 Feb 13, 2023	SELL	$16.14 - $23.55 $383,712 - $559,877	-23,774 Reduced 16.18%	123,174 $2.86 Million
Q3 2022 Nov 14, 2022	SELL	$15.46 - $20.1 $1.73 Million - $2.25 Million	-111,773 Reduced 43.2%	146,948 $2.35 Million
Q2 2022 Aug 11, 2022	BUY	$14.22 - $20.88 $1.94 Million - $2.86 Million	136,736 Added 112.09%	258,721 $4.58 Million
Q1 2022 May 11, 2022	SELL	$17.2 - $22.5 $287,463 - $376,042	-16,713 Reduced 12.05%	121,985 $2.48 Million
Q4 2021 Feb 10, 2022	BUY	$17.5 - $21.35 $1.74 Million - $2.12 Million	99,191 Added 251.07%	138,698 $2.59 Million
Q3 2021 Nov 12, 2021	BUY	$17.75 - $25.39 $701,249 - $1 Million	39,507 New	39,507 $780,000

Others Institutions Holding COLL

# of Institutions

258

Shares Held

37.6M

Call Options Held

53.7K

Put Options Held

200

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.57B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Collegium Pharmaceutical, Inc Transaction History